利培酮可降低精神分裂症合并可卡因依赖患者的渴望及复发率。
Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence.
作者信息
Smelson David A, Losonczy Miklos F, Davis Craig W, Kaune Maureen, Williams John, Ziedonis Douglas
机构信息
Department of Veterans Affairs, VISN 3 Mental Illness, Research, Education and Clinical Center, Lyons, New Jersey, USA.
出版信息
Can J Psychiatry. 2002 Sep;47(7):671-5. doi: 10.1177/070674370204700710.
OBJECTIVE
To examine the efficacy of atypical neuroleptics for decreasing craving and drug relapses during protracted withdrawal in individuals dually diagnosed with schizophrenia and cocaine dependence.
METHOD
We conducted a 6-week, open-label pilot study comparing risperidone with typical neuroleptics in a sample of withdrawn cocaine-dependent schizophrenia patients.
RESULTS
Preliminary results suggest that individuals treated with risperidone had significantly less cue-elicited craving and substance abuse relapses at study completion. Further, they showed a trend toward a greater reduction in negative and global symptoms of schizophrenia.
CONCLUSION
Atypical neuroleptics may help reduce craving and relapses in this population. Future research should include more rigorous double-blind placebo-controlled studies with this class of medications.
目的
研究非典型抗精神病药物对同时患有精神分裂症和可卡因依赖的个体在长期戒断期间减少渴求及药物复吸的疗效。
方法
我们进行了一项为期6周的开放标签试点研究，在已戒断可卡因依赖的精神分裂症患者样本中，将利培酮与典型抗精神病药物进行比较。
结果
初步结果表明，接受利培酮治疗的个体在研究结束时，由线索引发的渴求及物质滥用复吸显著减少。此外，他们在精神分裂症的阴性及整体症状方面有更大程度减轻的趋势。
结论
非典型抗精神病药物可能有助于减少该人群的渴求及复吸。未来的研究应包括对此类药物进行更严格的双盲安慰剂对照研究。
Zotero 插件